Ongoing research and development activities
First written in FY2019-Q3. 16 of 23 entries say "Restated". Latest entry: FY2026-H1.
97 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「R&D expenditure for the six months ended was ¥43 million . There were no material changes in the status of the Group’s R&D activities during the six months ended.」
The company recorded R&D expenses of ¥43 million and stated that there were no material changes in the status of its R&D activities. - FY2025AdvancedAnnual report
「As a result, we confirmed that ferulic acid and swertiamarin extract temporarily relax tight junctions and promote skin permeation, and obtained a patent on 3 June 2025.」
Joint research with Nagoya University and a Nagoya University startup confirmed an effect promoting penetration, and a patent was obtained on 3 June 2025. The results are being used in products including PERFECT ONE and PERFECT ONE FOCUS. - FY2025-H1RestatedAnnual report
「R&D expenditure for the six months ended was ¥39 million . There were no material changes in the status of the Group’s R&D activities during the six months ended.」
R&D expenses of ¥39 million were recorded, and it was stated that there had been no significant changes in R&D activities. - FY2024AdvancedAnnual report
「In our collagen research, we obtained a patent on 5 April 2024 for the manufacturing method of Protect Collagen, a proprietary ingredient developed to improve collagen penetration and barrier function.」
Recorded R&D expenditure of ¥92 million and obtained a patent for the manufacturing method of Protect Collagen. Research results concerning Murasaki and multiple proprietary collagen types were also presented at academic conferences and elsewhere. - FY2024-Q2RestatedAnnual report
「R&D expenditure for the six months ended was ¥54 million. There were no material changes in the status of the Group’s R&D activities during the six months ended.」
Recorded R&D expenditure of ¥54 million and stated that there were no material changes in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「R&D expenditure for the three months ended was ¥24 million . There were no material changes in the status of the Group’s R&D activities during the three months ended.」
R&D activities continued, with R&D expenditure of ¥24 million for the three months ended and no material changes in the status of those activities. - FY2023AdvancedAnnual report
「During the consolidated fiscal year, through joint research with Hiroshima University, a national university corporation, we discovered a proprietary lactic acid bacterium from Murasaki, our proprietary medicinal plant. … We succeeded in developing Murasaki Fermented Collagen. … In May 2023, we incorporated it into and launched Perfect One Moisture Gel, a Perfect One product.」
Recorded R&D expenditure of ¥100 million and developed a proprietary lactic acid bacterium and Murasaki Fermented Collagen through joint research with Hiroshima University. In May 2023, these were incorporated into and launched in a major product. - FY2023-Q3RestatedAnnual report
「R&D expenditure for the nine months ended was ¥69 million . There were no material changes in the status of the Group’s R&D activities during the nine months ended.」
The company recorded research and development expenses of ¥69 million and states that there were no significant changes in the status of research and development activities. - FY2023-Q2RestatedAnnual report
「R&D expenditure for the six months ended was ¥49 million . There were no material changes in the status of the Group’s R&D activities during the six months ended.」
Recorded R&D expenditure of ¥49 million and stated that there were no material changes in the status of R&D activities. - FY2023-Q1RestatedAnnual report
「R&D expenditure for the three months ended was ¥20 million . There were no material changes in the status of the Group’s R&D activities during the three months ended.」
Recorded R&D expenditure of ¥20 million and stated that there were no material changes in the status of R&D activities. - FY2022-Q3RestatedAnnual report
「R&D expenditure for the nine months ended was ¥82 million . There were no material changes in the status of the Group’s R&D activities during the nine months ended.」
Recorded R&D expenditure of ¥82 million and stated that there were no material changes in the status of R&D activities. - FY2022-Q2RestatedAnnual report
「R&D expenditure for the six months ended was ¥62 million. There were no material changes in the status of the Group’s R&D activities during the six months ended.」
Recorded R&D expenditure of ¥62 million and stated that there were no material changes in the status of R&D activities. - FY2022-Q1RestatedAnnual report
「R&D expenditure for the three months ended was ¥28 million. There were no material changes in the status of the Group’s R&D activities during the three months ended.」
The company recorded ¥28 million in R&D expenses and stated that there were no material changes in its R&D activities. - FY2021AdvancedAnnual report
「During the consolidated fiscal year, we advanced the proprietary development of Placenta Collagen as part of our materials research. We confirmed that Placenta Collagen contains approximately 9 times more collagen than ordinary placenta extract, and that its effects are enhanced when used with EGF, which promotes skin turnover. We successfully developed Placenta Collagen and obtained a decision to grant a patent for a new manufacturing method in September 2021.」
Recorded R&D expenditure of ¥143 million and advanced the development of Placenta Collagen, confirmation of its approximately 9-fold collagen content, acquisition of a patent grant for its manufacturing method, and applications to new brands. - FY2021-Q3RestatedAnnual report
「R&D expenditure for the nine months ended was ¥108 million. There were no material changes in the status of the Group’s R&D activities during the nine months ended.」
Recorded R&D expenditure of ¥108 million and stated that there were no material changes in the status of R&D activities. - FY2021-Q2RestatedAnnual report
「R&D expenditure for the six months ended was ¥78 million. There were no material changes in the status of the Company’s R&D activities during the six months ended.」
R&D activities continued, with R&D expenditure of ¥78 million and no material changes in the status of those activities. - FY2021-Q1RestatedAnnual report
「R&D expenditure for the three months ended was ¥28 million. There were no material changes in the status of the Company’s R&D activities during the three months ended.」
R&D activities continued, with R&D expenditure of ¥28 million for the three months ended and no material changes in the status of those activities. - FY2020AdvancedAnnual report
「During the fiscal year, we incorporated Protect Collagen (Note 1), an original ingredient jointly developed with a raw-material manufacturer, into Perfect One Lifting Gel and relaunched the product. We confirmed that it promotes collagen production at approximately 5 times the level of general collagen raw materials (Note 3). We plan to use it in the Perfect One series from FY2021 onward.」
Recorded R&D expenditure of ¥169 million, incorporated Protect Collagen into a product and relaunched it, and confirmed approximately 5 times the collagen-production-promoting effect. The Company also presented plans to use it in the series from FY2021 onward. - FY2020-Q3RestatedAnnual report
「R&D expenditure for the nine months ended was ¥141 million. There were no material changes in the status of the Company’s R&D activities during the nine months ended.」
R&D activities continued, with R&D expenditure of ¥141 million and no material changes in the status of those activities. - FY2020-Q2RestatedAnnual report
「R&D expenditure for the six months ended was ¥97 million. There were no material changes in the status of the Company’s R&D activities during the six months ended.」
R&D activities continued, with R&D expenditure of ¥97 million and no material changes in the status of those activities. - FY2020-Q1RestatedAnnual report
「R&D expenditure for the three months ended was ¥48 million. There were no material changes in the status of the Company’s R&D activities during the three months ended.」
R&D activities continued, with R&D expenditure of ¥48 million for the three months ended and no material changes in the status of those activities. - FY2019AdvancedAnnual report
「We incorporate “Compound Collagen EX,” a proprietary combination of 7 types of collagen, including an original raw material, into the Perfect One All-in-One Beauty Serum Gel series. During the fiscal year, we developed Protect Collagen, an original ingredient representing a new approach that adds “protective” and “penetration” functions to collagen’s “moisturizing” function, for the first time in the world.」
R&D expenditure was ¥176 million, with specific results including the development of Protect Collagen and the launches of Perfect One One Minute, W Health Green Juice, Kioku Leaf, and Multivitamins & Minerals. - FY2019-Q3First statedAnnual report
「R&D expenditure for the nine months ended was ¥99 million.」
R&D expenditure for the nine months ended was disclosed.